367 related articles for article (PubMed ID: 16465458)
21. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
[TBL] [Abstract][Full Text] [Related]
22. Subgroup differences in 'brain-type' transferrin and α-synuclein in Parkinson's disease and multiple system atrophy.
Yoshihara A; Fukatsu M; Hoshi K; Ito H; Nollet K; Yamaguchi Y; Ishii R; Tokuda T; Miyajima M; Arai H; Kato T; Furukawa K; Arai H; Kikuchi A; Takeda A; Ugawa Y; Hashimoto Y
J Biochem; 2016 Aug; 160(2):87-91. PubMed ID: 26970280
[TBL] [Abstract][Full Text] [Related]
23. Analysis of colonic alpha-synuclein pathology in multiple system atrophy.
Pouclet H; Lebouvier T; Coron E; Rouaud T; Flamant M; Toulgoat F; Roy M; Vavasseur F; Bruley des Varannes S; Neunlist M; Derkinderen P
Parkinsonism Relat Disord; 2012 Aug; 18(7):893-5. PubMed ID: 22560049
[TBL] [Abstract][Full Text] [Related]
24. Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker.
Chung SJ; Kim J; Lee HJ; Ryu HS; Kim K; Lee JH; Jung KW; Kim MJ; Kim MJ; Kim YJ; Yun SC; Lee JY; Hong SM; Myung SJ
Mov Disord; 2016 Feb; 31(2):241-9. PubMed ID: 26686342
[TBL] [Abstract][Full Text] [Related]
25. A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α-Synuclein in Parkinson's Disease.
Wang L; Wang G; Duan Y; Wang F; Lin S; Zhang F; Li H; Li A; Li H
Neurodegener Dis; 2019; 19(5-6):204-210. PubMed ID: 32485710
[TBL] [Abstract][Full Text] [Related]
26. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
[TBL] [Abstract][Full Text] [Related]
27. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease.
Chung CC; Chan L; Chen JH; Hung YC; Hong CT
Biomolecules; 2021 May; 11(5):. PubMed ID: 34067663
[TBL] [Abstract][Full Text] [Related]
28. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
[TBL] [Abstract][Full Text] [Related]
29. Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.
Ding J; Zhang J; Wang X; Zhang L; Jiang S; Yuan Y; Li J; Zhu L; Zhang K
J Neural Transm (Vienna); 2017 Mar; 124(3):353-360. PubMed ID: 27878377
[TBL] [Abstract][Full Text] [Related]
30. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Huang Y; Song YJ; Murphy K; Holton JL; Lashley T; Revesz T; Gai WP; Halliday GM
Acta Neuropathol; 2008 Dec; 116(6):639-46. PubMed ID: 18936941
[TBL] [Abstract][Full Text] [Related]
31. Familial Parkinson's point mutation abolishes multiple system atrophy prion replication.
Woerman AL; Kazmi SA; Patel S; Aoyagi A; Oehler A; Widjaja K; Mordes DA; Olson SH; Prusiner SB
Proc Natl Acad Sci U S A; 2018 Jan; 115(2):409-414. PubMed ID: 29279394
[TBL] [Abstract][Full Text] [Related]
32. Gender differences in Parkinson's disease: focus on plasma α-synuclein.
Caranci G; Piscopo P; Rivabene R; Traficante A; Riozzi B; Castellano AE; Ruggieri S; Vanacore N; Confaloni A
J Neural Transm (Vienna); 2013 Aug; 120(8):1209-15. PubMed ID: 23328951
[TBL] [Abstract][Full Text] [Related]
33. Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease.
Emmanouilidou E; Papagiannakis N; Kouloulia S; Galaziou A; Antonellou R; Papadimitriou D; Athanasiadou A; Bozi M; Koros C; Maniati M; Vekrellis K; Ioannou PC; Stefanis L
Parkinsonism Relat Disord; 2020 Apr; 73():35-40. PubMed ID: 32234683
[TBL] [Abstract][Full Text] [Related]
34. Serum adiponectin levels between patients with Parkinson's disease and those with PSP.
Kataoka H; Sugie K
Neurol Sci; 2020 May; 41(5):1125-1131. PubMed ID: 31897945
[TBL] [Abstract][Full Text] [Related]
35. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.
Yang SY; Chiu MJ; Lin CH; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH
J Nanobiotechnology; 2016 Jun; 14(1):41. PubMed ID: 27278241
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of the amount of α-synuclein in ischemic stroke and Parkinson's disease.
Zhao HQ; Li FF; Wang Z; Wang XM; Feng T
Neurol Sci; 2016 May; 37(5):749-54. PubMed ID: 26829934
[TBL] [Abstract][Full Text] [Related]
37. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control.
Lin WC; Lu CH; Chiu PY; Yang SY
Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863
[TBL] [Abstract][Full Text] [Related]
38. α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls.
Smith LM; Schiess MC; Coffey MP; Klaver AC; Loeffler DA
PLoS One; 2012; 7(12):e52285. PubMed ID: 23284971
[TBL] [Abstract][Full Text] [Related]
39. Alpha-synuclein in erythrocyte membrane of patients with multiple system atrophy: A pilot study.
Liu G; Tian C; Gao L; Cao Z; Feng T
Parkinsonism Relat Disord; 2019 Mar; 60():105-110. PubMed ID: 30228038
[TBL] [Abstract][Full Text] [Related]
40. Active immunization therapies for Parkinson's disease and multiple system atrophy.
Schneeberger A; Tierney L; Mandler M
Mov Disord; 2016 Feb; 31(2):214-24. PubMed ID: 26260853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
